Key facts
- This page summarizes Stephen Michael Kelsey's Form 4 filing for Revolution Medicines, Inc. (RVMD).
- 12 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 15 Sep 2026, 18:00.
Stephen Michael Kelsey - 11 Sep 2026 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)
- Reporting relationship
- Senior Advisor to the Chief Executive Officer
- Issuer ticker
- RVMD
- Reported as of
- 11 Sep 2026
- Net transaction value
- -$18,724,767
- SEC form
- 4
- Accepted by SEC
- 15 Sep 2026, 18:00:04 UTC
- Prior SEC filing
- 18 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen Michael Kelsey filed Form 4 for Revolution Medicines, Inc. (RVMD) on 15 Sep 2026.
Change
- Previous filing in this sequence was filed on 18 Jun 2026.
- Current net transaction value: -$18,724,767.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001462808
Primary reporting owner
Kelsey Stephen Michael
- Relationship
- Senior Advisor to the Chief Executive Officer
- Address
- REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY
- Signature
- /s/ Jack Anders, as Attorney-in-fact for Stephen Michael Kelsey
- Signature date
- 15 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RVMD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +52,500
- Change %
- +18%
- Price
- $42.45*
- Shares after
- 344,376
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
RVMD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +40,031
- Change %
- +12%
- Price
- $40.74*
- Shares after
- 384,407
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1
RVMD
transaction
Common Stock
Sale
- Transaction value
- $158,840
- Shares
- -800
- Change %
- -0.21%
- Price
- $198.55
- Shares after
- 383,607
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F2
RVMD
transaction
Common Stock
Sale
- Transaction value
- $2,367,955
- Shares
- -11,833
- Change %
- -3.1%
- Price
- $200.11
- Shares after
- 371,774
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F3
RVMD
transaction
Common Stock
Sale
- Transaction value
- $2,683,986
- Shares
- -13,368
- Change %
- -3.6%
- Price
- $200.78
- Shares after
- 358,406
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F4
RVMD
transaction
Common Stock
Sale
- Transaction value
- $4,326,947
- Shares
- -21,447
- Change %
- -6%
- Price
- $201.75
- Shares after
- 336,959
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F5
RVMD
transaction
Common Stock
Sale
- Transaction value
- $3,831,550
- Shares
- -18,869
- Change %
- -5.6%
- Price
- $203.06
- Shares after
- 318,090
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F6
RVMD
transaction
Common Stock
Sale
- Transaction value
- $3,659,309
- Shares
- -17,949
- Change %
- -5.6%
- Price
- $203.87
- Shares after
- 300,141
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F7
RVMD
transaction
Common Stock
Sale
- Transaction value
- $1,023,189
- Shares
- -4,995
- Change %
- -1.7%
- Price
- $204.84
- Shares after
- 295,146
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F8
RVMD
transaction
Common Stock
Sale
- Transaction value
- $672,991
- Shares
- -3,270
- Change %
- -1.1%
- Price
- $205.81
- Shares after
- 291,876
- Date
- 11 Sep 2026
- Ownership
- Direct
- Footnotes
- F1, F9, F10
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RVMD
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -52,500
- Change %
- -100%
- Price
- $42.45*
- Shares after
- 0
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,500
- Exercise price
- $42.45
- Footnotes
- F1, F11
RVMD
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -40,031
- Change %
- -31%
- Price
- $40.74*
- Shares after
- 88,069
- Date
- 11 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 128,100
- Exercise price
- $40.74
- Footnotes
- F1, F12
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 12 footnotes
Footnote F1
Transaction made pursuant to a 10b5-1 trading plan adopted by Stephen Kelsey on June 12, 2026.
Footnote F2
The transaction was executed in multiple trades at prices ranging from $198.35 to $198.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F3
The transaction was executed in multiple trades at prices ranging from $199.36 to $200.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F4
The transaction was executed in multiple trades at prices ranging from $200.36 to $201.33, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F5
The transaction was executed in multiple trades at prices ranging from $201.39 to $202.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F6
The transaction was executed in multiple trades at prices ranging from $202.41 to $203.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F7
The transaction was executed in multiple trades at prices ranging from $203.45 to $204.42, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F8
The transaction was executed in multiple trades at prices ranging from $204.46 to $205.45, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F9
The transaction was executed in multiple trades at prices ranging from $205.57 to $206.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Footnote F10
Includes 76,251 restricted stock units.
Footnote F11
Fully vested.
Footnote F12
One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
SEC remarks
Senior Advisor to the Chief Executive Officer